



Course on Molecular Pathology and Targeted Therapy in Gynaecological Cancers

Scientific Programme

Chairs: Ledermann, Matias-Guiu, Lorusso

April 3-4, 2023

London, UK

Day 1 – April 3, 2023			
08:00	<i>Registration at the venue and welcome coffee</i>		
08:45	Introduction Welcome – Purpose of the course	Chairs: Ledermann, Matias-Guiu, Lorusso	
	Session 1: Molecular Markers in High Grade Ovarian Cancer	Chairs: Ledermann and Matias-Guiu	
9:00	P53 mutations and immunological markers- what do they signify?	McCluggage	0:20
9:20	BRCA mutations – Pathological and Variants of unknown significance and other genes associated with hereditary ovarian cancer	George	0:20
9:40	Discussion		0:10
9:50	Precursor lesions and the model of development of high-grade ovarian cancer	Croce	0:20
10:10	Discussion		0:10
10:20	<i>Coffee break</i>		
10:40	Angiogenic pathways- significance in ovarian cancer and role of targeted anti-angiogenic therapy	Ledermann	0:20
11:00	Discussion		0:10
11:10	CA125 and serological markers of ovarian cancer- Anything new in last decade?	Leary	0:20
11:30	Homologous Recombination Repair - How should HRD be determined and is it clinically useful? (incl. ovarian and endometrial cancers)	George	0:20
11:50	Targeting HR Deficiency- when and with which agents?	Ledermann	0:20
12:10	Non-HRD high grade ovarian cancer- the dark side of the moon. Markers of drug resistance	Gourley	0:20
12:30	Discussion		0:15
12:45	<i>Lunch</i>		
13:45	Understanding immune profiles in ovarian cancer	Ganesan	0:20
14:05	Discussion		0:10
14:15	Immunotherapy of ovarian cancer- where are we now, and where is it going?	Ledermann	0:20
14:35	Discussion		0:10
	Session 2: Low Grade Ovarian Cancers	Chairs: Lorusso and Croce	
14:45	Molecular and genetic pathways and characteristics of low-grade cancers (serous and others)	McCluggage	0:20
15:05	Targeted therapy for low grade cancers	Gourley	0:20
15:25	Discussion		0:10
15:35	<i>Coffee break</i>		

	Session 3: Rare ovarian tumours	Chairs: Ledermann and Ganesan	
15:55	Molecular and Genetic identifiers as potential therapeutic targets in clear cell carcinomas	Matias-Guiu	0:20
16:15	Pathology/Molecular characteristics of Germ Cell tumours	Kaur	0:20
16:35	Molecular pathology of sex cord tumours	McCluggage	0:20
16:55	Discussion		0:10
17:05	Wrap up Day 1		
20:00	Welcome Dinner		
Day 2 – April 4, 2023			
	Session 4: Endometrial Cancers	Chairs: Joura and McCluggage	
8:30	New molecular classification of Endometrial cancers: routine pathology diagnostics in endometrioid and non-endometrioid cancers?	Matias-Guiu	0:20
8:50	Lynch Syndrome, DNA repair genes, microsatellite instability	Matias-Guiu	0:20
9:10	Discussion		0:10
9:20	Immuno-targeted therapy of Endometrial Cancer	Lorusso	0:20
9:40	Discussion		0:10
9:50	Using the molecular classification of Endometrial Cancers to select adjuvant therapies	Leary	0:20
10:10	Discussion		0:10
10:20	<i>Coffee break</i>		0:20
	Session 5: Rare uterine tumours	Chairs: Gourley and George	
10:40	Molecular pathology Mesenchymal tumours of the uterus	Croce	0:20
11:00	Discussion		0:10
11:10	Molecular and genetic characteristics of Trophoblastic tumours	Kaur	0:20
11:30	Discussion		0:10
11:40	<i>Lunch</i>		1:00
	Session 6: Cervical and vulvar Cancer	Chairs: Leary and Matias-Guiu	
12:40	HPV- role as a driver for carcinogenesis and a biomarker for diagnosis of cervical cancer; molecular pathology of cervical and vulvar cancer + Vaccination strategies and the prevention of cervical and vulvar cancer	Joura	0:30
13:10	Discussion		0:10
13:20	Immunotherapy and Immuno-targeting HPV as a therapeutic strategy	Lorusso	0:20
13:40	Discussion		0:10
	Session 7: Case studies	Chairs: Ledermann, Lorusso, Matias-Guiu	
13:50	Case study 1 (interactive) – carcinosarcoma	Case author / Matias-Guiu	0:10
14:00	Discussion		0:15
14:15	Case study 2 (interactive)- mesenchymal tumour	Case author / Croce	0:10
14:25	Discussion		0:15
14:40	Wrap up Day 2, evaluation, departures	Ledermann, Lorusso, Matias-Guiu	